Targets › BMP2
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 4; Other; next expected readout Dec 2027.
Growth factor of the TGF-beta superfamily that plays essential roles in many developmental processes, including cardiogenesis, neurogenesis, and osteogenesis. Induces cartilage and bone formation. (UniProt, P12643)
Open in Phaseline: the race on BMP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | Demineralized Bone Matrix/Bone Morphogenic Protein (DBM/BMP) Bone morphogenic protein with demineralized bone matrix to promote alveolar bone formation | BMP2, BMP7 | Phase 4 | Cleft Lip and Palate | Jan 2028 |
| Locate Bio | LDGraft 0.5mg/cc rhBMP-2 Recombinant human bone morphogenetic protein-2 (rhBMP-2) bone graft substitute | BMP2 | Phase 1 | Degenerative Disc Disease | Dec 2027 |
Degenerative Disc Disease (2) Cleft Lip and Palate (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.